Table 3.

Number and % of patients with at least one event in ivabradine/placebo groups for primary and secondary endpoints

	Ivabradine group n = 20	Placebo group n = 18
Primary endpoint components
Cardiovascular death or HF hospitalization	10 (50%)	10 (56%)
Cardiovascular death	6 (30%)	8 (44%)
Hospital admission for worsening HF	8 (40%)	8 (44%)
Secondary endpoints
Death of any cause	7 (35%)	9 (50%)
Hospitalization for any cause	13 (65%)	10 (56%)
Death from heart failure	4 (20%)	5 (28%)
Other
Non‐cardiovascular hospitalization	6 (30%)	2 (11%)
AMI hospitalization or death	0	0
Other cardiovascular hospitalization	3 (30%)	5 (28%)
Other cardiovascular death	0	2 (11%)
Non‐cardiovascular death	1 (5%)	1 (6%)
Sudden cardiac death	2 (10%)	1 (6%)

AMI; acute myocardial infarction; HF, heart failure.